In a study of 1,685 patients treated with CPA, elevated liver enzymes were seen in 10% of patients at a dosage of 50 mg/day and in 20% of patients at a dosage of greater than 100 mg/day.  A study of 2,506 patients given 18–136 mg/day for less than 48 months per patient reported a rate of %.   In a trial of 89 prostate cancer patients who received high-dose CPA for 4 years, there were elevated liver enzymes in % of the patients.  Yet another study of 105 patients found a hepatotoxicity rate of %, with serious hepatic injury occurring in %.  In 2002, it was reported that there were 18 case reports of CPA-associated hepatitis in the medical literature, with 6 of the cases resulting in death.  In addition, a review article cited a report of 96 instances of hepatotoxicity that were attributed to CPA, and 33 of these instances resulted in death.  Moreover, a 2014 review found that 15 cases specifically of CPA-induced fulminant (sudden-onset and severe) liver failure had been reported to date, with only one of these cases not resulting in death.  As such, the prognosis of CPA-induced liver failure is death.